Cognitive relapse after discontinuation of drug therapy in Alzheimer's disease: Cholinesterase inhibitors versus nootropics

Journal of Neural Transmission

Volumn 108, Issue 11, 2001, Pages 1327-1333

  Rainer, M ^a   Mucke, H A M ^b   Kruger Rainer C ^a   Kraxberger, E ^a   Haushofer, M ^a   Jellinger, K A ^c  

^a DANUBE HOSPITAL   (Austria)

^b HM Pharma Consultancy   (Austria)

^c LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Alzheimer disease; Cholinesterase inhibitor; Cognition; Dementia; Donepezil; Galantamine; Nootropic drugs; Open clinical trial; Rivastigmine

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CHOLINESTERASE INHIBITOR; DONEPEZIL; ERGOT ALKALOID; GALANTAMINE; GINKGO BILOBA EXTRACT; NOOTROPIC AGENT; PEPTIDE DERIVATIVE; PIRACETAM; RIVASTIGMINE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN VENTRICLE DILATATION; CLINICAL ARTICLE; COGNITIVE DEFECT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; GENOTYPE; HUMAN; MALE; PRIORITY JOURNAL; RELAPSE; SEX DIFFERENCE;

ACETYLCHOLINESTERASE; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; APOLIPOPROTEIN E4; APOLIPOPROTEINS E; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0035211514     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s007020100009     Document Type: Article

References (10)

1. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease
2. Metrifonate treatment of AD: Influence of APOE genotype
3. Apolipoprotein E genotype allele 4 and response to tacrine in Alzheimer's disease
4. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease
5. Apolipoprotein E4 allele as predictor of cholinergic deficits and treatment outcome in Alzheimer disease
6. Besteht eine korrelation zwischen dem klinischen schweregrad und dem makromorphologischen befund im CCT bei patienten mit DAT?
7. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
8. The apolipoprotein E ε4 allele and the response to tacrine therapy in Alzheimer's disease
9. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
10. Efficacy of acetylcholinesterase inhibitors versus nootropics in Alzheimer's disease: A retrospective, longitudinal study